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Abstract: Folate is a generic term for a water-soluble B-complex vitamin which plays an 
 important role in protein synthesis and metabolism and other processes related to cell multi-
plication and tissue growth. Pregnant and lactating women are at increased risk of folic acid 
deficiency because generally their dietary folate is insufficient to meet their physiological 
requirements and the metabolic demands of the growing fetus. The evidence pertaining to the 
reduction of the risk of neural tube defects (NTDs) due to folate is so compelling that supple-
mentation with 400 µg of folic acid to all women trying to conceive until 12 weeks of pregnancy 
has been recommended by every relevant authority. A recent Cochrane review has also found 
protective effects of folate supplementation in occurrence and reoccurrence of NTDs. Despite 
food fortification and targeted public health campaigns promoting folic acid supplementation, 
4,300,000 new cases occur each year worldwide resulting in an estimated 41,000 deaths and 
2.3 million disability-adjusted life years (DALYS). This article will review the burden and 
risk factors of NTDS, and the role of folate in preventing NTDs. It will also describe different 
modes of supplementing folate and the newer evidence of the effectiveness of adding folate in 
oral contraceptives for raising serum and red blood cell folate levels.
Keywords: folate, folate-containing oral contraceptives, oral contraceptives, contraceptives
Burden of neural tube defects  
and its natural history
Neural tube defects (NTDs), which include anencephaly, spina bifida, and  encephalocele, 
are congenital malformations that arise during the structural development of the neural 
tube, a process that is completed within 28 days after conception.
Anencephaly is invariably associated with death either as stillbirth, neonatal death 
or occasionally postneonatal death. Encephalocele and spina bifida may be associated 
with neonatal death, infant death or with impairment which is frequently severe in 
the absence of surgery including lower limb paralysis, incontinence, convulsions and 
frequent central nervous system (CNS) infections. Less severe defects include spina 
bifida occulta which can also have long-term neurological sequelae, but rarely causes 
neonatal death (Table 1).1
NTDs are an important cause of mortality and morbidity globally with a conser-
vative estimated incidence of 4,300,000 new cases a year2 resulting in an estimated 
41,000 deaths and 2.3 million disability-adjusted life years (DALYS).3 In addition, the 
lifetime direct cost associated with spina bifida is US$279,210.4 They thus comprise 
about one-tenth of the burden of all neonatal mortality5 and 10% of all congenital 
conditions and constitute the third largest congenital burden after congenital heart 
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disease and Down’s syndrome.3 Over 95% of all NTDs are 
first occurrence; with a small proportion being repeat events 
in women with a previously affected pregnancy.6 Risk factors 
include genetic factors, environmental factors, particularly 
folic acid deficiency at the time of conception, diabetes 
and obesity and other predisposing maternal factors.7 The 
prevalence of NTDs varies in different racial and ethnic 
groups,8,9 particularly in consanguineous marriages leading 
to genetic abnormalities,10 causing NTDs in current and 
recurrence in subsequent pregnancies.7,11 Environmental 
risk factors include maternal diabetes,12 use of valproic 
acid,13 hyperthermia,14,15 obesity,16–18 occupational exposure 
to agricultural19 and cleaning products.20,21 In most studies, 
the countries where a folate-rich diet is not available to all, 
NTDs are highest among the economically disadvantaged 
population subgroups.22–25 Even in high-income countries, 
lower maternal education status is associated with higher 
risk of NTDs.23,26 Over the past decades many countries 
have reported a reduction in prevalence of NTDs at birth 
mainly because of second-trimester screening and termina-
tion of affected pregnancies27 and partly because of folic acid 
supplementation.28
Certain gene polymorphisms are responsible for folate 
metabolism and are associated with decreased folate  absorption 
thus increasing folate needs. One of the prominent  variants 
are the methylene-tetrahydrofolate reductase (MTHFR) 
gene and Solute carrier family 19 (folate transporter), 
member 1 (SLC19A1) gene.29 With reduced folate intake in 
diet, MTHFR and SLC19A1 genetic variations are associated 
with increased risk of NTDs and conotruncal defects in the 
offspring.30–32 It was found to be associated with more than 
80 genetic abnormalities (trisomy 13 and 18 and autosomal 
recessive syndromes, such as Meckel–Gruber). On the other 
hand, environmental factors, including nutrition, are thought to 
contribute to about 5% to 10% of total birth defects.33
These conditions can be diagnosed antenatally. Elevated 
concentration of alpha-feto-protein in maternal serum can 
raise the suspicion of NTD; the diagnosis can further be estab-
lished by ultrasound examination during the second trimester 
of pregnancy. Unfortunately, these tests are not  routinely 
done in most developing countries as yet.34–36 However, the 
combinations of maternal serum screening programs and 
sonographic findings have enabled the  prenatal diagnosis 
of spina bifida in more than 90% of cases.37 Although the 
prenatal diagnosis of spina bifida maximizes the  reproductive 
options for women, it is yet unclear which fetuses would 
benefit from prenatal therapy, because the natural history 
and the sonographic signs of progressive neurologic damage 
have not been well characterized.
Role of folic acid in prevention  
of neural tube defects
Folate is a generic term for a water soluble B-complex 
 vitamin, and it serves as co-factor in transfer of single carbon 
during the methylation cycle responsible for the synthesis of 
DNA, neurotransmitters, and gene expression.38,39 Folate also 
plays an important role in protein synthesis and metabolism 
and other processes related to cell multiplication and tissue 
growth.40 The main consequence of folate deficiency in 
adults is megaloblastic anemia, characterized by abnormally 
large red cell precursors in the bone marrow and larger than 
normal red cells in the peripheral blood. The methylation of 
homocysteine to produce methionine (both essential amino 
acids) uses 5-Methylene-tetrahydrofolate (5-MTHF) (folate 
and folic acid are metabolized to 5-MTHF during its  passage 
across the intestinal mucosa) as the methyl donor in the 
 reaction. In folate deficiency, homocysteine accumulates in 
the serum and is found to be associated with an increased 
risk in cardiovascular disease,41 late pregnancy  complications 
such as pre-eclampsia,42–44 and NTDs around the time of 
conception.40
Pregnant and lactating women are at increased risk of 
folic acid deficiency because generally their dietary folate 
is insufficient to meet the physiological requirements and 
Table 1 Categories of neural tube defects, their causes and prognosis
Anencephaly Encephalocele Spina bifida
Cause Failure of closure of the anterior 
(cranial) neural arch
Failure of closure of the anterior  
(cranial) neural arch at a later stage  
of embryogenesis than anencephaly
Failure of closure of the posterior 
(cranial) vertebral arch
Prognosis Stillbirth or neonatal death Mortality from meningitis Disability ranges from 
Neurological: sensory and motor defects, 
learning disability and epilepsy 
Orthopedics: contractures, joint 
dislocations, and talipes 
Functional: bladder and bowel dysfunction
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the metabolic demands of the mother and the growing 
fetus.45,46
In 1991, a multicenter, multinational randomized preven-
tion trial by the British Medical Research Council (MRC) 
Vitamin Study Group, presented the first beneficial impacts 
of folic acid supplementation.46 The study was initiated in 
1983 and was halted in 1991, when it was felt that the results 
warranted the prescription of folic acid supplementation to 
all study participants. The study enrolled 1817 women who 
had a previous pregnancy with an infant or fetus with a neural 
tube abnormality and were planning another pregnancy. In this 
study, one group was given 4000 µg of folic acid, the second 
group a multivitamin with 4000 µg of folic acid, the third 
group was given no supplementation, while the final group 
received a multivitamin without folic acid. The analysis of 
the trial results showed that folic acid supplementation was 
associated with a 71% reduction in NTDs. The study also 
demonstrated that such results were achieved only when 
supplementation began before conception and continued 
through the first three months of the pregnancy.
In a span of a year, another major trial from Hungary 
presented their results of folic acid supplementation on 
women without a previous history of NTD pregnancy. The 
results from this trial indicated that a multiple micronutrient 
supplement containing 800 µg of folic acid prevented the 
occurrence of NTDs.47
While maternal intake of folate and folic acid is specifi-
cally associated with a decreased risk for NTDs, the results 
from those trials showed that it also provides protection 
for other selected birth defects. Approximately half of the 
birth defects are limited to a single organ and the other 
half frequently present additional birth defects.48 Affected 
infants also face difficulty with feeding and later with speech 
development, hearing and tooth formation. Malnutrition 
and infection can further lead to severe illness and, in some 
cases, death.48
A recent Cochrane review of f ive trials involving 
6105 women (1949 with a history of a pregnancy affected by 
an NTD and 4156 with no history of NTDs), shows a protective 
effect of daily folic acid supplementation in doses ranging from 
360 µg to 4000 µg a day, with and without other vitamins and 
minerals, before conception and up to 12 weeks of pregnancy, 
for preventing the occurrence of NTDs by 72% (relative risk 
[RR] 0.28; 95% confidence intervals [CI]: 0.15–0.52) and 
reoccurrence by 68% (RR 0.32; 95% CI: 0.17–0.60).49
Another review published in International Journal of 
Epidemiology in 2010 presented the meta-analysis of eight, 
population based observational studies examining the impact 
of folic acid fortified food and reported reduced NTDs 
incidence (RR 0.54; 95% CI: 0.46–0.63).50
Sources of folic acid and rationale 
for the fortification of oral 
contraceptives
Folate is naturally present in legumes, lentils, kidney beans, 
green peas, corn, beets, leafy green vegetables (such as 
 spinach, broccoli, iceberg lettuce, asparagus, and turnip 
greens) and some citrus fruits and juices (such as oranges, 
strawberries, and tomato). Folic acid is the synthetic and most 
stable form of folate and is often used in supplements and for-
tified foods. The bioavailability of folic acid is approximately 
70% higher in fortified foods than that of folate naturally con-
tained in foods, although there are wide variations depending 
on the methodology used in the measurement.51
In 1992, after the emergence of evidence of reduced 
occurrence of NTDs with folic acid supplementation, the 
World Health Organization (WHO) recommended 400 µg 
of folic acid to all women trying to conceive until 12 weeks 
of pregnancy.52 Since then daily supplementation with folic 
acid, in addition to iron, is routinely recommended for all 
pregnant women to prevent anemia.53 Women are usually 
supplemented with folic acid tablets, however, in many 
countries governments have also introduced the concept of 
folate-fortified food programs, in which folic acid is added 
to flour, maize, or cereals to increase serum folate levels in 
the population.
While fortification is felt to be the best way to ensure 
that women of child-bearing age receive supplementation in 
the months preceding pregnancy and in the critical window 
when a woman might not know that she is pregnant, folic 
acid supplementation does not ensure this. Women not on 
folate supplementation who unintentionally become pregnant 
may be late in starting folate supplementation, and thus 
fail to reach the required levels to reduce the risk of NTDs, 
even if they initiate oral supplementation the moment their 
pregnancy is established.
As most women of reproductive age do not get 
adequate amounts of folate in their diets and do not seek 
preconceptional care, it is obvious that newer approaches are 
needed to reach women at risk for pregnancy. Hence recently, 
fortifying oral contraceptive with folate was tested and 
recommended by the United Nations and the US Food and 
Drug Administration (FDA) with the reason that women may 
become pregnant during use or shortly after discontinuation, 
possibly before seeking preconception counseling from their 
healthcare  provider. It is particularly important for women 
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who want to use an oral contraceptive, to offer them daily 
folate supplementation. The oral contraceptive as a vehicle to 
supply folate is important because its users are sexually active 
and it is the most popular method of birth control, especially 
among young women, who are the age group with the greatest 
number of pregnancies both intended and unintended. It not 
only raises plasma and red blood cells (RBC) folate levels 
but also provides required folate levels until women adopt 
another effective contraceptive method or become pregnant 
and initiate folic acid supplementation.
Safety, tolerability and efficacy 
studies on folate containing oral 
contraceptives
In 2010, the FDA approved Beyaz® and Safyral® (Bayer 
Health Care Pharmaceuticals Inc, Wayne, NJ) oral contracep-
tives, which have both estrogen (20 µg ethinyl estradiol) and 
progestin (3000 µg of drospirenone) and also contain a folate 
(451 µg levomefolate calcium – also known as 5-MTHF and 
L-methylfolate). Two clinical trials have examined the effects 
of these folate-containing oral contraceptives on RBC folate 
levels which became the basis of this drug aproval.54–57
The US Benefit study compared an oral contraceptive 
containing drospirenone and ethinyl estradiol plus folate 
with the nonfolate-fortified version of the oral contracep-
tive in a multicenter, double-blind, randomized active-
controlled trial on 379 healthy women aged 18–40 years 
who had been exposed to folate-fortified food.57,58 Folate 
levels were assessed in the plasma and RBC every 2 weeks 
for the 24-week study period. The women using the folate-
fortified oral contraceptives demonstrated significant increase 
(15.8 nmol/L) in serum folate levels. These levels were 
consistently maintained throughout the study period. In the 
nonfolate-fortified arm, plasma folate levels decreased by 
2.2 ± 14.6 nmol/L. Significant differences were also seen in 
the mean RBC folate levels. In the control group, RBC folate 
levels increased by 34.3 nmol/L, while in the folate-fortified 
oral contraceptive users, a mean increase from baseline of 
419.9 ± 347 nmol/L (P , 0.001) was observed.
The European Long-term Folate Study, on the other hand, 
compared the combination of folate in an oral contraceptive 
given orally in a cyclic regimen for 24 weeks (6 cycles), with 
the same oral contraceptive administered separately with 
folic acid tablets in German women who had no exposure 
to folate-fortified food.54,55 It was a double-blind, 24-week 
trial followed by an open-label 20-week follow-up with a 
nonfortified oral contraceptive to evaluate the elimination 
of folate from the body over time. At each point in time, the 
folate-fortified oral contraceptive women had higher levels of 
folate in both serum and RBC than women who took the folic 
acid supplements in addition to oral contraceptives. During 
the second phase of follow up, folate levels were found to be 
diminished but remained over the baseline levels.
While the importance of folate-fortifying oral contracep-
tives was established by these two trials and the persistence 
of the elevation in folate levels was quantified, for some clini-
cians, supplementing oral contraceptives with folate seems 
counterintuitive. Notwithstanding, birth control pills represent 
the most popular contraceptive choice, although they have a 
relatively high failure rate. Thus, an oral contraceptive that 
contains folate has appeal and full potential to supplement 
women with folate at the time of conception.
Given the potential individual and public health benefits, 
folate-containing oral contraceptives have some overlapping 
adverse reactions across three indications: contraception, acne, 
and folate supplementation. The most common treatment-
emergent adverse reactions are headache/migraine, menstrual 
irregularities (spotting, metrorrhagia, and  menorrhagia), nausea/
vomiting, and breast pain/tenderness.59 At the same time, oral 
contraceptives are contraindicated in women with a high risk of 
arterial or venous thrombotic diseases, undiagnosed abnormal 
uterine bleeding, breast cancer or other hormone-sensitive cancer, 
liver tumors (benign or malignant) or liver disease, conditions 
that predispose to hyperkalemia (ie, renal impairment, hepatic 
dysfunction, and adrenal insufficiency), or who are pregnant.59
Conclusions and future directions
Neural tube closure occurs during the first month after con-
ception, often before a woman is aware of her pregnancy 
status. The potential to reduce the incidence of NTDs with 
folate supplementation is well established based on a body 
of evidence derived from randomized, controlled trials. 
Every relevant authority recommends that all women of 
childbearing potential consume at least 400 µg of folic acid 
daily. There are many ways to obtain supplemental folic acid. 
The folate-containing oral contraceptive is a novel way to 
increase folic acid levels in women of childbearing age who 
choose birth control pills for contraception. While the FDA 
has approved this drug based on two clinical trials from devel-
oped countries, the drug still requires assessment in terms of 
its efficacy and effectiveness in different age groups and in 
regions with low contraceptive prevalence rates. This might 
not be effective in the context of the developing world as 
contraceptive usage rates are not comparable to the developed 
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world. Coverage rates need to be improved for contraceptives 
in these regions; also efforts need to be made to strategize 
effective means of folic acid delivery in these regions.
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The authors report no conflicts of interest in this work.
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